标签： 上海后花园私人会所

U20 national football team beats South Korea! There will be three good news.

On March 12th, Beijing time, the U20 Asian Youth Championship will usher in the quarter-finals. China’s U20 men’s soccer team will play against South Korea’s and China’s U20 men’s soccer team will beat South Korea, which will usher in three good news:

1. China U20 will qualify for the World Youth Championship.

Qualifying for the World Youth Championship is very important for us, because all the echelons of our men’s soccer team have not participated in the world series for a long time, which shows that we have been derailed from the world. If we still can’t qualify for the world series, the gap between us will only get bigger and bigger.

2. Send more football talents to the country.

Judging from this U20 national team, there are still a few good young players in the team, the opportunity maker of captain Alfredo, and every goal in several group matches is related to Alfredo, the brain of U20 men’s soccer team. As the goalkeeper of China U20 men’s soccer team, Li Hao has wonderful saves in every game, which is the most important threshold for our defense.

3. Reject fear of Korea

Although we have broken the fear of Korea before, we can beat South Korea. For our current youth army, we are not afraid of South Korea from the heart. After this group enters the national team, it is also a kind of confidence for the China men’s football team.

Nature writes： In the next 30 years, cancer will cost the world 25 trillion US dollars.

Monoclonal antibody against B-cell psoriasis leukemia, a target of cancer artificial intelligence

①Nature：Cancer will cost the world $25 trillion over next 30 years

In the next 30 years, cancer may cost the world $25 trillion.

DOI :10.1038/d41586-023-00634-9

②Seminars in Cancer Biology：Artificial intelligence in cancer immunotherapy: applications in neoantigen recognition, antibody design and immunotherapy response prediction

Review: Application and development of artificial intelligence in the field of precision oncology: new antigen recognition, antibody design and immunotherapy response prediction.

DOI :10.1016/j.semcancer.2023.02.007

③Molecular Cancer：CD39/CD73/A2AR pathway and cancer immunotherapy

Review: New progress in pathophysiological function of CD39/CD73/A2AR pathway in cancer development, metastasis and drug resistance.

DOI :10.1186/s12943-023-01733-x

④Immunity：B cell receptor signaling in germinal centers prolongs survival and primes B cells for selection

B cell receptor signal transduction in germinal center prolongs the survival of B cells and initiates the selection of B cells.

DOI :10.1016/j.immuni.2023.02.003

⑤Frontiers in Immunology：Metabolic rewiring in keratinocytes by miR-31-5p identifies therapeutic intervention for psoriasis

The metabolic recombination of miR-31-5p in keratinocytes determines the intervention on psoriasis.

DOI :10.15252/emmm.202215674

⑥Journal of Hematology & Oncology：Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting

The latest drug research and new scheme progress of American Society of Hematology (ASH) for acute myeloid leukemia (AML)
DOI :10.1186/s13045-023-01411-x

⑦FDA extended the review of adult Roctavian with severe hemophilia A because of "significant changes in a large number of additional data"

⑧ A small molecule MET inhibitor, gumetinib, which was developed by Shanghai Institute of Pharmacology, China Academy of Sciences, was approved for marketing, and it was used for locally advanced or metastatic non-small cell lung cancer (NSCLC) with the jump mutation (METex14 jump) in exon 14 of mesenchymal-epithelial transforming factor (MET).

⑨ The clinical study of Relma-cel targeting CD19 for first-line high-risk large B-cell lymphoma was officially launched.

⑩ Lilly will terminate the research and development of Solanezumab for Alzheimer’s disease because it fails to slow down the cognitive decline of preclinical Alzheimer’s patients.

The world of scientific exploration is full of challenges. AtaGenix pays tribute to every pioneer and is more committed to becoming your trusted partner!